Longevity drug developer Loyal and pain therapy manufacturer Elanco Animal Health are working with the organization to promote the need for aging canine care and enhance veterinary resources.
Loyal
Latest Content
Loyal’s developmental therapy aims to increase longevity and quality of life for senior dogs
Brennen McKenzie, VMD, MSc, MA, director of veterinary medicine at Loyal, a biotechnology company, and a clinical practitioner, discusses the use of lab values as predictors for disease.
Brennen McKenzie, VMD, MSc, MA, discusses how metabolic dysfunction impairs health in older dogs, in a dvm360 interview.
Scholl brings extensive entrepreneurial experience and technical innovation to help Loyal deliver world’s first FDA-approved longevity drug
Advertisement
Advertisement
Trending on dvm360
1
Canadian dog treats recalled due to Salmonella contamination
2
Generic antimicrobial product is approved by the FDA
3
Clinic center: New Chewy Vet Care clinic features viewing treatment window
4
Akston launches clinical trial for novel canine cancer therapy
5
